These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9631890)

  • 21. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
    Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE
    N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inner clot diffusion and permeation during fibrinolysis.
    Diamond SL; Anand S
    Biophys J; 1993 Dec; 65(6):2622-43. PubMed ID: 8312497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV; Frank JD; Craft TJ; Sundboom JL; Smith GF
    J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT; Francis CW; Marder VJ
    J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT; Driscoll EM; White AJ; Sherigill A; Giboulot TA; Lucchesi BR
    J Pharmacol Exp Ther; 2003 Aug; 306(2):616-23. PubMed ID: 12734394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
    Stehling F; Weber R; Ozcelik A; Bröcker M; Volbracht L; Diener HC; Busch E
    Neurosci Lett; 2008 Aug; 441(1):39-43. PubMed ID: 18597942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of fibrinolysis and thrombolytic therapy].
    Kudinov SO
    Ukr Biokhim Zh (1999); 2000; 72(4-5):90-8. PubMed ID: 11200459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
    Curl GR; Jakubowski JA; Deykin D; Bush HL
    Circulation; 1986 Sep; 74(3 Pt 2):I21-4. PubMed ID: 3091289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model.
    Hashimoto M; Oiwa K; Matsuo O; Ueshima S; Okada K; Okada Y; Okamoto S; Giddings JC; Yamamoto J
    Thromb Haemost; 2003 May; 89(5):820-5. PubMed ID: 12719778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage.
    Stewart D; Kong M; Novokhatny V; Jesmok G; Marder VJ
    Blood; 2003 Apr; 101(8):3002-7. PubMed ID: 12446443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
    Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
    Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.
    Collen D; Stump D; van de Werf F; Jang IK; Nobuhara M; Lijnen HR
    Circulation; 1985 Aug; 72(2):384-8. PubMed ID: 3924437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
    Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
    Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Position and developmental trends in fibrinolytic therapy].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):6-17. PubMed ID: 2427416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.